Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099191 | 0.81 | FKBP1A (0.55) | LMNAMAPTHTTKDM4E | |
| SCHEMBL16099508 | 0.77 | DPP4 (0.57) | DPP4DPP8 | |
| SCHEMBL10213631 | 0.75 | TACR3 (0.65) | P2RX7TACR3 | |
| SCHEMBL13245865 | 0.74 | NOTUM (0.47) | P2RX7NOTUMTACR3DRD2DRD3 | |
| SCHEMBL16099875 | 0.73 | KDM4E (0.49) | P2RX7KDM4E | |
| SCHEMBL9557181 | 0.72 | CYP1A2 (0.65) | NAAALMNAMAPTHTTKDM4E | |
| SCHEMBL16099817 | 0.72 | KMT2A (0.54) | P2RX7LMNAKDM4E | |
| SCHEMBL16099846 | 0.70 | HTT (0.56) | LMNAHTTKDM4E | |
| SCHEMBL9556998 | 0.70 | NAAA (0.53) | NAAADPP4 | |
| SCHEMBL17509126 | 0.70 | DPP4 (0.59) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | NAAA 903/4885P2RX7 464/4885NOTUM 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.